Downloads: 259

Files in This Item:
File Description SizeFormat 
s10096-011-1523-4.pdf362.27 kBAdobe PDFView/Open
Title: Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia.
Authors: Matsumura, Y  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-8595-8944 (unconfirmed)
Yamamoto, M  kyouindb  KAKEN_id
Matsushima, A  kyouindb  KAKEN_id
Nagao, M  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-8886-6145 (unconfirmed)
Ito, Y
Takakura, S  kyouindb  KAKEN_id
Ichiyama, S  kyouindb  KAKEN_id
Author's alias: 松村, 康史
Keywords: cefotaxime
bloodstream infection
risk factor
prognosis
ESBL
AmpC
Issue Date: 1-Aug-2012
Publisher: Springer-Verlag
Journal title: European journal of clinical microbiology & infectious diseases
Volume: 31
Issue: 8
Start page: 1931
End page: 1939
Abstract: We investigated the performance of cefotaxime for the detection of extended-spectrum β-lactamase (ESBL) or plasmid-mediated AmpC β-lactamase (pAmpC) and the clinical characteristics of cefotaxime-non-susceptible Escherichia coli or Klebsiella pneumoniae (CTXNS-EK) bacteraemia. All of the consecutive bloodstream isolates between 2005 and 2010 in a Japanese university hospital were characterised using polymerase chain reaction (PCR). Risk factors and outcomes of CTXNS-EK were analysed by multivariate logistic regression analysis. We identified 58 CTXNS-EK (15.6%) from 249 E. coli and 122 K. pneumoniae. Cefotaxime with a minimum inhibitory concentration (MIC) of >1 μg/mL had a sensitivity of 98.3% and a specificity of 99.7% for the detection of ESBL or pAmpC. CTXNS-EK had increased from 4.5% in 2005 to 23% in 2009. Risk factors for CTXNS-EK were previous isolation of multidrug-resistant bacteria, use of oxyimino-cephalosporins or fluoroquinolones, and high Sequential Organ Failure Assessment (SOFA) score. Patients with CTXNS-EK bacteraemia less frequently received appropriate empirical therapy than patients with cefotaxime-susceptible EK bacteraemia (81% vs. 97%, p<0.001) and died within 30 days (21% vs. 5%, p=0.001). Using the current breakpoints of the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST), cefotaxime alone can identify ESBL or pAmpC producers. CTXNS-EK is an important and increasingly prevalent bacteraemia pathogen.
Rights: The final publication is available at link.springer.com
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/178037
DOI(Published Version): 10.1007/s10096-011-1523-4
PubMed ID: 22210267
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.